25 years of coronary angioplasty: almost a fairy tale

  title={25 years of coronary angioplasty: almost a fairy tale},
  author={Bernhard Meier and D{\"o}lf Bachmann and Thomas Felix L{\"u}scher},
  journal={The Lancet},
ISCHEMIA trial: How to apply the results to clinical practice
The approach based on the ISCHEMIA study and the pretest probability for a positive test in patients with chronic coronary syndromes is proposed, which underscores the benefits of disease-modifying OMT for stable coronary artery disease patients.
Drug-Coated Balloon for De Novo Coronary Artery Lesions: A Systematic Review and Trial Sequential Meta-analysis of Randomized Controlled Trials
Investigating the efficacy of drug-coated balloon (DCB) treatment for de novo coronary artery lesions in randomized controlled trials (RCTs) found that for patients at bleeding risk, DCB treatment was superior to BMS in TLR and the rate of bailout stenting was lower and decreased gradually.
Durable polymer everolimus-eluting stents: history, current status and future prospects
Durable polymer everolimus-eluting stent, supported by much evidence, has demonstrated its efficacy and safety, not only in de novo artery lesions, but in multiples scenarios, such as the acute setting and diabetic population, becoming one of the most polyvalent stents available.
Future Prospects of PCI for CTO
Catheter procedures for the cardiovascular system have made rapid progress over a period of approximately 40 years since Dr. Gruntzig first performed percutaneous coronary balloon angioplasty in
Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting.
This second document focuses on features of culprit and vulnerable coronary plaques, offers guidance on when to adopt an intracoronary imaging-guided approach, and provides an appraisal of intravascular imaging-derived metrics to define the haemodynamic significance of coronary lesions.